RxDoctor Payments Data

Young Kang, MD

Psychiatry · Welsh, LANPI 1861424293

Payments from drug & device makers

$1,952in general payments, 2019–2025

Across 81 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$486
  • Lilly USA, LLC$284
  • Johnson & Johnson$225
  • Novo Nordisk$225
  • AstraZeneca$205
  • AbbVie$162
  • plus $365 from 7 others

What the payments were for

  • Food & beverage$1,944100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,952 in reported general payments places this provider in the 70th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$35,688
Medicare patients
51
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$30,416
EliquisApixaban53$16,489
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$16,040
MounjaroTirzepatide11$12,678
XareltoRivaroxaban26$10,943
TrulicityDulaglutide11$10,629
JardianceEmpagliflozin34$8,329
LantusInsulin Glargine,hum.Rec.Anlog51$4,553
Divalproex Sodium101$2,980
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,502
Atorvastatin Calcium352$2,167
Midodrine Hcl28$2,136
Potassium Chloride159$1,932
Furosemide324$1,739
Sucralfate97$1,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$225$31,38242 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$284$24,21187 claims
PfizerEliquis$486$16,48953 claims
GSKTrelegy Ellipta$109$16,04028 claims
Johnson & JohnsonXarelto$225$10,94326 claims
Sanofi-aventis U.S. LLCLantus$37$4,55351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Welsh

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →